Molecular Pharmacology (USA), Ltd. (MLPH)

0.0006 0.0000 (0.00%) As of 09:31AM EDT. Market open.

Molecular Pharmacology (USA), Ltd.

Drug Discovery Centre
284 Oxford Street Leederville
Perth, WA 6007
Australia
61 8 9443 3011

Sector(s): Financial Services
Industry: Shell Companies
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jeffrey D. Edwards	CEO, President, CFO & Director	N/A	N/A	1951

Amounts are as of 31 December 2013, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.

Corporate governance

Molecular Pharmacology (USA), Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.